Dosage / Direction for Use
Adult Lipanthyl NT 145 mg 1 tab/day. Lipanthyl Supra 160 mg 1 tab/day. Lipanthyl 67M 3 cap/day.
Administration
NT tab: May be taken with or without food: Swallow whole w/ a glass of water, SUPRA MR tab: Should be taken with food: Swallow whole.
Contraindications
Hypersensitivity to peanut, arachis oil or soya lecithin. Known photoallergy or phototoxic reaction during treatment w/ fibrates or ketoprofen. Hepatic insufficiency (including biliary cirrhosis & unexplained persistent liver function abnormality); known gallbladder disease; severe chronic kidney disease; chronic or acute pancreatitis w/ the exception of acute pancreatitis due to severe hypertriglyceridemia.
Special Precautions
Secondary causes of hyperlipidemia eg, uncontrolled type 2 DM, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment, alcoholism. Hyperlipidemic patients taking estrogens or OCs containing estrogen. Monitor transaminase levels every 3 mth during the 1st 12 mth of therapy & thereafter periodically. Discontinued if AST & ALT levels increase to >3 times the ULN range & if symptoms of hepatitis occur (eg, jaundice, pruritus). Pancreatitis; muscle toxicity, predisposing factors for myopathy &/or rhabdomyolysis. Measure creatinine during the 1st 3 mth after initiation of therapy & thereafter periodically. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Pregnancy & lactation. Childn <18 yr. Lipanthyl NT 145 mg Fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
Side Effects / Adverse Reactions
Increased blood homocysteine level. GI signs & symptoms (abdominal pain, nausea, vomiting, diarrhea, flatulence); increased transaminases.
Interactions
Enhanced oral anticoagulant effect & may increase risk of bleeding. Severe cases of reversible renal function impairment w/ cyclosporine. Increased risk of serious muscle toxicity w/ HMG-CoA reductase inhibitors or other fibrates. Reversible paradoxical reduction of HDL-cholesterol w/ glitazones. Caution when used w/ CYP2C19, CYP2A6 & CYP2C9 metabolized drugs w/ narrow therapeutic index.